Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-90
SponsorMayo Clinic
About this trial
This study will evaluate if the sponge capsule device can accurately detect the presence of Barrett's Esophagus and prevalent dysplasia/adenocarcinoma detection, in a screening population, with and without chronic gastroesophageal reflux disease.
Eligibility criteria
Qualifiers
Male and female ages 50-85
Patients who have three or more risk factors for Barrett's Esophagus.
Diagnosis
Use of one of the following drugs >= 3 months over the last 5 years: omeprazole, esomeprazole, pantoprazole, rabeprazole, dexlansoprazole, lansoprazole, ranitidine, famotidine, cimetidine
Disqualifiers
esophageal adenocarcinoma/cancer
esophageal squamous carcinoma
endoscopic ablation for Barrett's esophagus
esophageal squamous dysplasia
Trial design
Treatments tested in this trial
- Sponge Capsule
Treatment groups
1,550 Participants
are divided into 3 treatment groupsSponsors and collaborators
Mayo Clinic
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov